CommercialPrior AuthLow impact
Alferon N® (interferon alfa-n3) (Revised)
Humana·Dermatology, Urology, Infectious Disease·Commercial
Effective date
Feb 28, 2024
We identified it
Jun 25, 2026
Summary
Humana revised its Alferon N (interferon alfa-n3) prior authorization policy for commercial plans, effective February 28, 2024. The policy requires prior authorization for intralesional treatment of condylomata acuminata in patients 18+ who have failed or are intolerant to imiquimod and other treatment modalities (surgery, laser, cryotherapy). Initial approval covers 8-week treatment durations. This is a routine policy update with no substantive changes to coverage criteria.
Action Required
By March 31, 2024: Billing team should verify that current prior authorization workflows for Alferon N are aligned with the revised February 28, 2024 policy. Confirm that the PAL (Preauthorization and Notification List) on www.humana.com/PAL reflects the current criteria (diagnosis of condylomata acuminata, age 18+, prior imiquimod treatment/contraindication/intolerance, and failure of other modalities). No immediate system changes required unless prior authorization processes were not previously in place. Medical and procedural coding information must be verified through the Humana PAL system, not from this policy document.